{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:09Z","timestamp":1787595729364,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["22HA1003"],"award-info":[{"award-number":["22HA1003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06974"],"award-info":[{"award-number":["JP23K06974"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Herein, we detail our experience with a unique patient with concomitant multiple sclerosis (MS) and idiopathic thrombocytopenic purpura (ITP) treated with ofatumumab, which resulted in stable disease activity and platelet count normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 21-year-old Japanese woman presented with medial longitudinal fasciculus syndrome and was subsequently diagnosed with MS. She was treated with methylprednisolone pulse therapy (1,000 mg\/day for 5 days). During her first hospitalization, her platelet count was low (40 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L). Based on investigations, serologic findings, and bone marrow aspiration, she was diagnosed with ITP. Following methylprednisolone treatment, oral prednisolone was initiated and gradually tapered. Glatiramer acetate was used as a disease-modifying drug (DMD). As prednisolone was tapered off, the platelet count decreased correspondingly. The clinical course included two MS relapses, each of which was treated with a methylprednisolone pulse and DMD adjustments (the DMT was sequentially switched from glatiramer acetate to dimethyl fumarate, then fingolimod, and finally natalizumab). Despite an initial recovery of the platelet count following these interventions, the platelet count declined correspondingly with the prednisolone dose reduction. Finally, the DMD was switched to ofatumumab, an anti-CD20 monoclonal antibody with pharmacological similarities to rituximab, a second-line treatment for ITP. After the initiation of ofatumumab, the patient remained clinically stable with no further MS relapses, and her platelet count stabilized over 2 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Herein, we report our experience with a novel case of MS concomitant with ITP that was safely treated with ofatumumab. Considering the pharmacological similarities of ofatumumab to rituximab (a second-line treatment for ITP), anti-CD20 monoclonal antibodies such as ofatumumab could be a promising treatment option for cases of MS concomitant with ITP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1515776","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T01:12:32Z","timestamp":1741655552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuki","family":"Yokota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.09.006","article-title":"Clustering and commonalities among autoimmune diseases","volume":"33","author":"Mackay","year":"2009","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03098.x","article-title":"Concomitant multiple sclerosis and idiopathic thrombocytopenic purpura","volume":"17","author":"Sahraian","year":"2010","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318227b23f","article-title":"Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab","volume":"77","author":"Stosic","year":"2011","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12890\/2016_000399","article-title":"Glatiramer acetate-associated refractory immune thrombocytopenic purpura","volume":"3","author":"Sagy","year":"2016","journal-title":"Eur J Case Rep Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220590","article-title":"Immune thrombocytopenic purpura associated with fingolimod","author":"Yuen","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517699876","article-title":"Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis","volume":"24","author":"Ranganathan","year":"2018","journal-title":"Mult Scler"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106081","article-title":"Fingolimod-induced immune thrombocytopenic purpura (ITP)","volume":"197","author":"Mukharesh","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-27","article-title":"Evidence of platelet activation in multiple sclerosis","volume":"5","author":"Sheremata","year":"2008","journal-title":"J Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature06559","article-title":"Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets","volume":"451","author":"Han","year":"2008","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46278","article-title":"Ofatumumab desensitization protocol: A case of refractory immune thrombocytopenic purpura","volume":"15","author":"Cochran","year":"2023","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427100-00005","article-title":"Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis","volume":"27","author":"Rieckmann","year":"2004","journal-title":"Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ajh.20028","article-title":"Case report of rituximab-induced thrombocytopenia","volume":"75","author":"Shah","year":"2004","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802010509","article-title":"Rituximab-induced severe acute thrombocytopenia: a case report and review of literature","volume":"26","author":"Dhand","year":"2008","journal-title":"Cancer Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9079-6","article-title":"Rituximab-induced acute thrombocytopenia: a case report and review of the literature","volume":"26","author":"Yi","year":"2009","journal-title":"Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9628-17","article-title":"Rituximab-induced acute thrombocytopenia in a patient with follicular lymphoma: A case report and review of the literature","volume":"57","author":"Omura","year":"2018","journal-title":"Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13256-021-02950-y","article-title":"Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report","volume":"15","author":"Yudhishdran","year":"2021","journal-title":"J Med Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.747","article-title":"Multiple sclerosis following splenectomy as a treatment for idiopathic thrombocytopenic purpura","volume":"44","author":"Matsui","year":"2005","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197511000-00002","article-title":"The human splenic suppressor cell","volume":"20","author":"Sampson","year":"1975","journal-title":"Transplantation"},{"key":"B24","article-title":"Suppressor activity of the human spleen and thymus","volume":"79","author":"Sampson","year":"1976","journal-title":"Surgery"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200004","article-title":"Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis","volume":"9","author":"von Essen","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T01:12:37Z","timestamp":1741655557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1515776"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1515776","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1515776"}}